Q5117 HCPCS code: Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
Q5117 is the HCPCS Level II code for injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg. In 2024 Medicare paid an average of $13.09 per service for Q5117 across 104,606 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 120 per day on outpatient hospital claims. Medicare volume fell 90% from 2022 to 2024 (1,075,416 to 104,606 services). In 2024, about 503 clinicians billed Medicare for Q5117 for 385 beneficiaries; California, Texas, Illinois accounted for 74% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-10-01 |
| Last action effective | 2019-10-01 |
Who bills Q5117 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 503 |
| Medicare beneficiaries | 385 |
| States with claims | 9 |
| Share of services in top 3 states (California, Texas, Illinois) | 74% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q5117, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 1,075,416 | 3,136 | $39.90 | $31.83 |
| 2023 | 438,432 | 1,580 | $27.10 | $21.52 |
| 2024 | 104,606 | 385 | $16.59 | $13.09 |
States with the most Q5117 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 35,684 | $13.42 |
| Texas | 15,951 | $13.38 |
| Illinois | 8,478 | $13.33 |
| Maryland | 6,939 | $13.72 |
| Ohio | 4,078 | $14.85 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 120 | Prescribing Information |
| practitioner claims | 120 | Prescribing Information |
What changed for Q5117
- 2019-10-01: Q5117 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5117?
Q5117 is the HCPCS Level II code for injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg. Short descriptor: "Inj., kanjinti, 10 mg".
How much does Medicare pay for Q5117?
In 2024, the average Medicare payment was $13.09 per service (average allowed $16.59).
Does Medicare cover Q5117?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of Q5117 can be billed per day?
120 on outpatient hospital claims; 120 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5117
- Watch Q5117 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5117
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.